KemPharm, Inc. (KMPH): Price and Financial Metrics


KemPharm, Inc. (KMPH): $7.86

-0.19 (-2.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KMPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

KMPH POWR Grades


  • KMPH scores best on the Quality dimension, with a Quality rank ahead of 85.1% of US stocks.
  • The strongest trend for KMPH is in Quality, which has been heading up over the past 43 weeks.
  • KMPH ranks lowest in Stability; there it ranks in the 7th percentile.

KMPH Stock Summary

  • With a year-over-year growth in debt of -97.56%, Kempharm Inc's debt growth rate surpasses merely 1.8% of about US stocks.
  • Revenue growth over the past 12 months for Kempharm Inc comes in at 131.21%, a number that bests 94.52% of the US stocks we're tracking.
  • Kempharm Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -40.08%, greater than the shareholder yield of just 8.17% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Kempharm Inc are KPTI, EPZM, FBIO, LOGC, and LQDA.
  • KMPH's SEC filings can be seen here. And to visit Kempharm Inc's official web site, go to kempharm.com.

KMPH Valuation Summary

  • In comparison to the median Healthcare stock, KMPH's price/earnings ratio is 224.66% lower, now standing at -45.5.
  • KMPH's price/sales ratio has moved NA NA over the prior 78 months.
  • KMPH's price/sales ratio has moved NA NA over the prior 78 months.

Below are key valuation metrics over time for KMPH.

Stock Date P/S P/B P/E EV/EBIT
KMPH 2021-08-31 106.2 23.1 -45.5 -305.7
KMPH 2021-08-30 101.8 22.1 -43.6 -292.3
KMPH 2021-08-27 101.4 22.0 -43.4 -291.2
KMPH 2021-08-26 101.5 22.1 -43.5 -291.6
KMPH 2021-08-25 105.1 22.8 -45.0 -302.2
KMPH 2021-08-24 109.4 23.8 -46.9 -315.3

KMPH Growth Metrics

  • Its 4 year price growth rate is now at -96.26%.
  • Its 5 year net cashflow from operations growth rate is now at 27.51%.
  • The 4 year cash and equivalents growth rate now stands at -96.71%.
KMPH's revenue has moved up $6,598,000 over the prior 15 months.

The table below shows KMPH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 28.434 10.228 -65.05
2021-06-30 28.394 11.907 -66.3
2021-03-31 23.316 -2.503 -54.746
2020-12-31 13.288 -1.939 -12.76
2020-09-30 12.298 -3.978 -13.941
2020-06-30 21.836 -5.156 -7.869

KMPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KMPH has a Quality Grade of B, ranking ahead of 90.29% of graded US stocks.
  • KMPH's asset turnover comes in at 0.451 -- ranking 100th of 682 Pharmaceutical Products stocks.
  • NAII, ACUR, and EGRX are the stocks whose asset turnover ratios are most correlated with KMPH.

The table below shows KMPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.451 1.000 -0.427
2021-03-31 0.745 1.000 -0.609
2020-12-31 1.218 1.000 -0.410
2020-09-30 1.146 1.081 -0.400
2020-06-30 1.958 1.000 -0.069
2020-03-31 1.318 1.000 -0.222

KMPH Price Target

For more insight on analysts targets of KMPH, see our KMPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.00 Average Broker Recommendation 1.75 (Moderate Buy)

KMPH Stock Price Chart Interactive Chart >

Price chart for KMPH

KMPH Price/Volume Stats

Current price $7.86 52-week high $19.68
Prev. close $8.05 52-week low $5.07
Day low $7.82 Volume 319,492
Day high $8.11 Avg. volume 1,659,649
50-day MA $9.21 Dividend yield N/A
200-day MA $10.12 Market Cap 277.61M

KemPharm, Inc. (KMPH) Company Bio


KemPharm Inc. provides biopharmaceutical services. The Company offers discovery and development of therapies for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and cardiovascular diseases.


KMPH Latest News Stream


Event/Time News Detail
Loading, please wait...

KMPH Latest Social Stream


Loading social stream, please wait...

View Full KMPH Social Stream

Latest KMPH News From Around the Web

Below are the latest news stories about Kempharm Inc that investors may wish to consider to help them evaluate KMPH as an investment opportunity.

KemPharm's (KMPH) CEO Travis Mickle on Q3 2021 Results - Earnings Call Transcript

KemPharm, Inc. (KMPH) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Jason Rando – Tiberend Strategic Advisors Travis Mickle – President and Chief Executive Officer LaDuane Clifton – Chief Financial Officer Rich Pascoe – Executive Chairman Conference Call Participants Presentation Operator Good day and thank...

SA Transcripts on Seeking Alpha | November 11, 2021

KemPharm EPS beats by $0.02, misses on revenue

KemPharm (NASDAQ:KMPH): Q3 GAAP EPS of -$0.06 beats by $0.02. Revenue of $1.97M (+3.7% Y/Y) misses by $0.18M. Press Release...

Seeking Alpha | November 10, 2021

KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates

Lead Independent Director Richard W. Pascoe Named Executive Chairman Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 10, 2021, 4:30 p.m. ET Corporate and Regulatory Highlights Appointment of Richard W. Pascoe as Executive Chairman; Mr. Pascoe to focus on executing the Company’s strategic growth plansUplisted to The Nasdaq Global Select MarketResearch involving AZSTARYS® and serdexmethylphenidate featured in poster presentations at multiple medical con

Yahoo | November 10, 2021

KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD

Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect Corium Continues Commercialization Effort in U.S. CELEBRATION, Fla., Nov. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS® will be featured in a poster presentation during the 2021 Virtual International Conference on ADH

Yahoo | November 5, 2021

KemPharm to Report Third Quarter 2021 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, November 10, 2021, 4:30 p.m. ET CELEBRATION, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 10, 2021, at 4:30 p.m. ET, to discuss its corporate and financial results for the third

Yahoo | November 3, 2021

Read More 'KMPH' Stories Here

KMPH Price Returns

1-mo -17.26%
3-mo -15.48%
6-mo -26.13%
1-year -55.34%
3-year -80.81%
5-year -86.35%
YTD -29.82%
2020 84.55%
2019 -78.69%
2018 -56.05%
2017 37.29%
2016 -85.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6899 seconds.